Article
Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.
Scientific reports - 12 Feb 2016
Zheng D, Ye X, Zhang M Z, Sun Y, Wang J Y, Ni J, Zhang H P, Zhang L, Luo J, Zhang J, Tang L, Su B, Chen G, Zhu G, Gu Y, Xu J F
Abstract excerpt
EGFR T790M mutation occurs in half of non-small cell lung cancer (NSCLC) patients with acquired EGFR-TKI (TKI) resistance, based on tumor re-biopsies using an invasive clinical procedure. Here, we dynamically monitored T790M mutation in circulating tumor DNA (ctDNA) using serial plasma samples from NSCLC patients receiving TKI through Droplet Digital PCR (ddPCR) method and the associations between overall...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.